Use of Novel Anti-inflammatory Agents to Inhibit Osteosarcoma Lung Metastasis release_uzwlaw243zh5nnmk6vmasosxzm

by Lauren Wierenga, University Of Calgary, University Of Calgary, Donna Senger

Published by University of Calgary.

2016  

Abstract

Currently the 5-year survival rate for osteosarcoma patients with pulmonary metastasis is less than 30%, identifying a need for novel approaches to inhibit metastasis. Consistent with an emerging understanding of the cancer-inflammation relationship, a requirement for neutrophils in metastasis was recently proposed. Here we assessed the potential requisite of neutrophils and the effects of two novel anti-inflammatory agents in osteosarcoma metastasis: LT-peptide and GML (GM1-Targeted Linoleate-Containing TLR2 Ligand). Using an osteosarcoma lung metastatic mouse model, we found increased neutrophil levels in the lungs in the presence of osteosarcoma cells and reduced metastatic burden following antibody-mediated neutrophil depletion or GML treatment. These preclinical studies identify targeting neutrophils as a novel therapeutic paradigm in osteosarcoma metastasis and contribute to our understanding of the mechanisms involved in metastatic osteosarcoma, thus supporting the development of anti-inflammatory therapies as a promising approach to improve the outcomes of osteosarcoma patients.
In text/plain format

Archived Files and Locations

application/pdf   17.6 MB
file_ttttuvv2ong7tjj7sylgmxemmi
prism.ucalgary.ca (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article
Stage   published
Date   2016-07-05
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 287ffc37-195d-412f-ab13-e1a09208e80a
API URL: JSON